Abstract
In-stent restenosis remains the limitation of coronary stent implantation despite numerous efforts of its prevention by catheter-based techniques or by drug therapy. Today, only intravascular irradiation has proven to effectively reduce neointima formation, restenosis rate and major adverse cardiovascular events by approximately 50%. Its efficiency is demonstrated for high-risk subsets like long lesions, lesions in saphenous venous bypass grafts or diabetic patients, indicating the extraordinary potential of vascular irradiation. Yet vascular irradiation has some limitations. Edge effect describes the phenomenon of excessive neointimal proliferation at the edges of an irradiated segment and is likely due to axial dose fall-off and / or barotrauma by the angioplasty procedure. Geographic miss, the combination of dose fall-off and vessel injury may be deleterious, especially if a new stent is implanted. The use of appropriate radiation source lengths to avoid geographic miss substantially reduces the incidence of edge effect. Late thrombosis, occurring even years after irradiation, had significantly diminished the benefit of vascular irradiation in initial clinical trials, but extension of ntiplatelet therapy up to 12 months after irradiation has reduced its rates to placebo levels. Vascular brachytherapy is of considerable clinical benefit in the prevention of restenosis and the only proven option for the treatment of in-stent restenotic lesions. This review will focus on the mechanisms of action of vascular irradiation, on the pathophysiological reasons for its complications and therapeutic options. Both angiographic and clinical results of randomised and observational studies will be updated in detail.
Keywords: in-stent restenosis, coronary angioplasty, intravascular irradiation, coronary stents, late thrombosis, edge effect
Current Pharmaceutical Design
Title: Intracoronary Brachytherapy - Clinical State and Pathophysiological Considerations
Volume: 11 Issue: 4
Author(s): Florian Krotz, Hae-Young Sohn, Volker Klauss and Thomas M. Schiele
Affiliation:
Keywords: in-stent restenosis, coronary angioplasty, intravascular irradiation, coronary stents, late thrombosis, edge effect
Abstract: In-stent restenosis remains the limitation of coronary stent implantation despite numerous efforts of its prevention by catheter-based techniques or by drug therapy. Today, only intravascular irradiation has proven to effectively reduce neointima formation, restenosis rate and major adverse cardiovascular events by approximately 50%. Its efficiency is demonstrated for high-risk subsets like long lesions, lesions in saphenous venous bypass grafts or diabetic patients, indicating the extraordinary potential of vascular irradiation. Yet vascular irradiation has some limitations. Edge effect describes the phenomenon of excessive neointimal proliferation at the edges of an irradiated segment and is likely due to axial dose fall-off and / or barotrauma by the angioplasty procedure. Geographic miss, the combination of dose fall-off and vessel injury may be deleterious, especially if a new stent is implanted. The use of appropriate radiation source lengths to avoid geographic miss substantially reduces the incidence of edge effect. Late thrombosis, occurring even years after irradiation, had significantly diminished the benefit of vascular irradiation in initial clinical trials, but extension of ntiplatelet therapy up to 12 months after irradiation has reduced its rates to placebo levels. Vascular brachytherapy is of considerable clinical benefit in the prevention of restenosis and the only proven option for the treatment of in-stent restenotic lesions. This review will focus on the mechanisms of action of vascular irradiation, on the pathophysiological reasons for its complications and therapeutic options. Both angiographic and clinical results of randomised and observational studies will be updated in detail.
Export Options
About this article
Cite this article as:
Krotz Florian, Sohn Hae-Young, Klauss Volker and Schiele M. Thomas, Intracoronary Brachytherapy - Clinical State and Pathophysiological Considerations, Current Pharmaceutical Design 2005; 11 (4) . https://dx.doi.org/10.2174/1381612053382025
DOI https://dx.doi.org/10.2174/1381612053382025 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cell and Gene Therapies in Cardiovascular Disease with Special Focus on the No Option Patient
Current Gene Therapy Extending Life Using Tissue and Organ Replacement
Current Aging Science Pulmonary Complications After Congenital Heart Surgery
Current Respiratory Medicine Reviews Bench to Bedside of CTLA-4: A Novel Immuno-Therapeutic Agent for Inflammatory Disorders
Recent Patents on Inflammation & Allergy Drug Discovery Antiplatelet Therapy in Children: Why So Different from Adults’?
Current Pharmaceutical Design A Novel, Biodegradable, Thermoresponsive Hydrogel Attenuates Ventricular Remodeling and Improves Cardiac Function Following Myocardial Infarction - a review
Current Pharmaceutical Design Advanced Therapies For End-Stage Heart Failure
Current Cardiology Reviews Pharmacovigilance Assessment of Cardiac Implications of Nicotine Replacement Therapy Among Smokers
Current Drug Safety Inhibitors of the Proteolytic Activity of Urokinase Type Plasminogen Activator
Current Pharmaceutical Design The Predictive Value of Lipid Markers in Vascular Disease
Current Pharmaceutical Design Meet Our Co-Editor
Cardiovascular & Hematological Agents in Medicinal Chemistry Is the Use of Autologous Platelet-Rich Plasma Gels in Gynecologic, Cardiac, and General, Reconstructive Surgery Beneficial?
Current Pharmaceutical Biotechnology Neuroinflammation is Associated with Brain Extracellular TAU-Protein Release After Spontaneous Subarachnoid Hemorrhage
Current Drug Targets Efficacy, Duration and Timing of Withdrawal of Prophylactic Treatment with Antiepileptic Drugs in Neurosurgical Conditions
Current Pharmaceutical Design Dual Energy Computed Tomography Angiography in the Peripheral Arterial Imaging: A Systematic Review of Image Quality, Radiation Dose and Diagnostic Value
Current Medical Imaging Understanding the Molecular and Cellular Changes Behind Aortic Valve Stenosis
Current Pharmaceutical Biotechnology The Wnt/β-catenin Signalling Pathway Inhibitor Sclerostin is a Biomarker for Early Atherosclerosis in Obesity
Current Neurovascular Research Microbleeds after Stent-assisted Coil Embolization of Unruptured Intracranial Aneurysms: Incidence, Risk Factors and the Role of Thromboelastography
Current Neurovascular Research Congenital Heart Disease: The Crossroads of Genetics, Epigenetics and Environment
Current Genomics Nutritional Control, Gene Regulation, and Transformation of Vascular Smooth Muscle Cells in Atherosclerosis
Cardiovascular & Hematological Disorders-Drug Targets